comparemela.com

Latest Breaking News On - Modified toxicity probability interval - Page 1 : comparemela.com

Perspective Therapeutics Completes Initial Dose Escalation Cohort for Second Novel Targeted Alpha Therapy

SEATTLE, Nov. 16, 2023 Perspective Therapeutics, Inc. , today announced the completion of cohort 1 dosing in the Phase 1/2a clinical trial of [212Pb]VMT-α-NET in patients with unresectable or.

United statesMarkus puhlmannNikolaos trikalinosExchange commissionPerspective therapeutics incUniversity of iowaOncologist at washington university in stDepartment of energyChief medical officerMedical oncologistWashington universityMayo clinicMaximum tolerated doseMaximum feasible doseModified toxicity probability intervalPerspective therapeutic

Perspective Therapeutics Completes Recruitment for First Patient Cohort in Phase 1/2a Dose Escalation Trial of VMT01 in Malignant Melanoma

SEATTLE, Oct. 16, 2023 Perspective Therapeutics, Inc. , today announced the completion of recruitment for the first patient cohort in its Phase 1/2a dose escalation study of 212Pb-VMT01 , its.

United statesMarkus puhlmannZacharys morrisExchange commissionDepartment of energyUniversity of wisconsin bentson research fellowshipPerspective therapeutics incChief medical officer markus puhlmannVice chairEndowed professorHuman oncologyProgram directorWisconsin bentson research fellowshipPrincipal investigatorMaximum toleratedMaximum feasible

vimarsana © 2020. All Rights Reserved.